Adenovirus-mediated gene transfer in the ovine pituitary gland is associated with hypophysitis

Journal of Endocrinology

Volumn 173, Issue 2, 2002, Pages 265-271

  Davis, J R E ^a   McMahon, R F T ^a   Lowenstein, P R ^a   Castro, M G ^a   Lincoln, G A ^a   McNeilly, A S ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; PROLACTIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; FEMALE; FIBROSIS; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; HISTOLOGY; HORMONE RELEASE; HUMAN CYTOMEGALOVIRUS; HYPOPHYSIS DISEASE; HYPOPHYSITIS; IMMUNOCYTOCHEMISTRY; INFLAMMATION; INFLAMMATORY INFILTRATE; LYMPHOCYTE; MARKER GENE; NONHUMAN; PRIORITY JOURNAL; SHEEP; TISSUE NECROSIS; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; BETA-GALACTOSIDASE; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; INFLAMMATION; INJECTIONS; MODELS, ANIMAL; NECROSIS; PITUITARY GLAND; PROLACTIN; SHEEP; TRANSFECTION;

EID: 0036106145     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.0.1730265     Document Type: Article

References (30)

1. New perspectives for gene therapy in endocrinology
2. Multihormonal regulation of the human prolactin gene - Expression from 5000 bp of its upstream sequence
3. Adenovirus gene transfer causes inflammation in the brain
4. Gene therapy strategies for the treatment of pituitary tumours
5. Expression of transgenes in normal and neoplastic anterior pituitary cells using recombinant adenoviruses: Long term expression, cell cycle dependency, and effects on hormone secretion
6. Molecular therapy in a model neuroendocrine disease: Developing clinical gene therapy for pituitary tumours
7. Tissue-specific consequences of the anti-adenoviral immune response: Implications for cardiac transplants
8. The spectrum and significance of primary hypophysitis
9. Review: Is pituitary gene therapy realistic?
10. Gene therapy for pituitary tumours
11. Cell-type specific adenoviral transgene expression in the intact ovine pituitary gland after stereotaxic delivery: An in vivo system for long-term multiple parameter evaluation of human pituitary gene therapy
12. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials
13. Strong promoters are the key to highly efficient, noninflammatory and noncytotoxic adenoviral-mediated transgene delivery into the brain in vivo
14. Immune responses to adenoviral vectors during gene transfer in the brain
15. Targeted expression of toxic genes directed by pituitary hormone promoters: A potential strategy for adenovirus-mediated gene therapy of pituitary tumors
16. Stereotactic injection of adenoviral vectors that target gene expression to specific pituitary cell types: Implication for gene therapy
17. Encephalic ventricles of the ewe (Ovis aries L.): Conformation, relations and stereotaxic topography
18. Gene therapy death prompts review of adenovirus vector
19. Stereotaxic approach to hypothalamic nuclei of the Shiba goat with radiographic monitoring
20. High efficiency method for gene transfer in normal pituitary gonadotropes: Adenoviral-mediated expression of G protein-coupled receptor kinase 2 suppresses luteinizing hormone secretion
21. Variation in the immune response to adenoviral vectors in the brain: Influence of mouse strain, environmental conditions and priming
22. Transcriptional targeting to anterior pituitary lactotrophic cells using recombinant adenovirus vectors in vitro and in vivo in normal and estrogen/sulpiride-induced hyperplastic anterior pituitaries
23. Long-term transgene expression within the anterior pituitary gland in situ: Impact on circulating hormone levels, cellular and antibody-mediated immune responses
24. Dynamic changes in prolactin promoter activation in individual living lactotrophic cells
25. Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: Toward realistic gene therapy for chronic diseases
26. Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain
27. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-deficient adenovirus vectors
28. Adenovirus-mediated herpes simplex virus type-1 thymidine kinase gene therapy suppresses oestrogen-induced pituitary prolactinomas
29. Immune responses to adenovirus vectors in the nervous system
30. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy